The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

默克（Merck）周二宣布，其重磅免疫疗法Keytruda与辉瑞（Pfizer）的抗体药物偶联物Padcev联合疗法，在治疗一种膀胱癌方面显示出积极成果。

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

辉瑞（Pfizer）周二宣布，其抗体药物偶联物Padcev与默克（Merck）的免疫疗法Keytruda联合使用，在治疗一种膀胱癌方面显示出积极效果。 这家美国生物制药公司表示，一项III期试验表明，在接受治疗的患者中，无事件生存期（研究的主要终点）出现了“具有临床相关性和统计学意义的改善”。两项次要终点也取得进展，包括总生存期的改善，以及与单独手术相比，对于不适合化疗的浸润性膀胱癌（MIBC）患 ...

Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove investor interest.

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world.

Merck is also working on different strategies to drive Keytruda's long-term growth. These include innovative immuno-oncology combinations, including Keytruda with LAG3 and CTLA-4 inhibitors.

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Merck & Co., Inc. (NYSE:MRK) is one of ...